Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxybutynin chloride
Drug ID BADD_D01644
Description Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]
Indications and Usage Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms.[L8648] On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.[T689]
Marketing Status approved; investigational
ATC Code G04BD04
DrugBank ID DB01062
KEGG ID D00722
MeSH ID C005419
PubChem ID 91505
TTD Drug ID D0R1DH
NDC Product Code 14539-653; 16729-318; 62175-271; 64980-209; 64980-431; 69315-182; 72888-032; 0904-2821; 43353-282; 50090-4622; 50268-629; 52817-260; 62135-508; 63739-548; 70934-909; 71335-0610; 71335-1494; 0615-8428; 16729-319; 43063-790; 50090-0318; 50090-6199; 50268-627; 54838-510; 65162-371; 65162-373; 67296-1175; 68084-610; 70518-1941; 70518-2388; 71205-667; 71335-2121; 71930-051; 62135-509; 63187-749; 65162-372; 70518-2710; 70518-2904; 71335-1690; 71610-277; 0615-3512; 72189-131; 50111-456; 65085-0013; 16729-317; 27241-156; 42291-635; 43353-322; 62175-270; 67544-569; 68788-7785; 70954-005; 71335-0519; 0603-4975; 53808-1122; 64980-211; 68788-8141; 71335-0669; 71610-394; 49169-1019; 65015-705; 51655-482; 63629-9689; 64980-531; 72189-132; 38779-0384; 59651-656; 10702-201; 66064-1005; 23155-810; 42291-633; 42291-914; 43063-851; 43353-285; 50458-810; 51407-099; 55154-0657; 60687-670; 62135-507; 62135-520; 62175-272; 64380-162; 64980-210; 69452-119; 71335-1160; 72789-049; 72888-031; 27241-157; 50458-805; 0023-5861; 68084-480; 70518-3473; 71335-1014; 72888-030; 0904-6570; 0904-7027; 51927-2455; 43353-978; 50090-5822; 50268-628; 67296-2045; 69452-120; 69452-121; 70518-2640; 70518-2688; 72189-130; 0832-0038; 54469-0007; 27241-155; 42291-634; 43063-931; 43353-284; 50090-4307; 51655-665
UNII L9F3D9RENQ
Synonyms oxybutynin | 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate | 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate | Zatur | Contimin | Cystonorm | Ditropan | Dridase | Cystrin | Dresplan | Driptane | gelnique | Gen-Oxybutynin | Novo-Oxybutynin | Nu-Oxybutyn | Oxyb AbZ | Oxybutin Holsten | Oxybuton | Oxybutynin AL | Oxybutynin AZU | Oxybutynin Heumann | Oxybutynin Hexal | oxybutynin hydrochloride | oxybutynin chloride | Oxybutynin Stada | oxybutynin von ct | Oxybutynin-Puren | Oxybutynin-ratiopharm | Oxymedin | Oxytrol | PMS-Oxybutynin | Pollakisu | Renamel | Ryol | Spasmex Oxybutynin | Spasyt | Tavor | Oxybugamma | Apo-Oxybutynin
Chemical Information
Molecular Formula C22H32ClNO3
CAS Registry Number 1508-65-2
SMILES CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Amblyopia06.02.01.001---
Asthenia08.01.01.001---
Constipation07.02.02.001--
Cycloplegia06.05.03.002; 17.17.02.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Hallucination19.10.04.003--
Hypohidrosis08.01.03.029; 23.02.03.005--
Insomnia17.15.03.002; 19.02.01.002--
Lacrimation decreased06.08.02.007---
Mydriasis06.05.03.004; 17.02.11.003---
Nausea07.01.07.001--
Palpitations02.11.04.012--
Rash23.03.13.001---
Restlessness17.02.05.021; 19.11.02.002--
Tachycardia02.03.02.007---
Urinary hesitation20.02.02.009---
Urinary retention20.02.02.011--
Vasodilation procedure25.03.01.001---
Gastrointestinal motility disorder07.02.03.001---
Erectile dysfunction19.08.04.001; 21.03.01.007--
Lactation insufficiency18.06.02.006; 21.05.02.006---
The 1th Page    1    Total 1 Pages